We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Maple Syrup Compound a Potent Anti-Inflammatory Agent

By LabMedica International staff writers
Posted on 04 Jan 2016
A substance that forms during the process that renders maple sap into syrup was found to have potent anti-inflammatory properties that may be developed into drugs for treatment of diseases characterized by chronic inflammation such as arthritis.

Investigators at Université Laval (Québec City, Canada) reported in the November 27, 2015, online edition of the journal Bioorganic & Medicinal Chemistry Letters that they had prepared and tested precursors of the polyphenolic compound quebecol and its derivatives. Analysis of maple sap before it was converted into syrup suggested quebecol was not naturally present in the sap but, instead, was formed during extraction or processing.

Image: Maple sap being transformed to syrup (Photo courtesy of Wikimedia Commons).
Image: Maple sap being transformed to syrup (Photo courtesy of Wikimedia Commons).

Experiments conducted with cultures of immune system macrophages demonstrated that quebecol had an anti-inflammatory effect on lipopolysaccharide (LPS)-induced NF-kappaB activation and inhibited the secretion of two pro-inflammatory cytokines, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).

Some derivatives of quebecol were even more effective than the original molecule. "The most powerful derivative has a simpler structure and is easier to synthesize than quebecol," said senior author Dr. Normand Voyer, professor of chemistry at Université Laval. "This paves the way for a whole new class of anti-inflammatory agents, inspired by quebecol, which could compensate for the low efficacy of certain treatments while reducing the risk of side effects."

Related Links:

Université Laval



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Drug Testing Assays
Atellica DT 250 Analyzer
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control

Latest BioResearch News

Researchers Classify 108 Lysosomal Disorders in Updated Diagnostic Framework
04 Jan 2016  |   BioResearch

New Autoantibody Target Identified in Neuromyelitis Optica Spectrum Disorder
04 Jan 2016  |   BioResearch

New Immune Target Could Support More Precise High Blood Pressure Treatment
04 Jan 2016  |   BioResearch